Dragos Damian, who returned to the CEO position at TerapiaRanbaxy drug maker last December, after having run the operationsof another two major producers, Zentiva and Actavis, says hispriority this year is to revert to growth after last year's 7%decline. "The goal is to have 10% growth in 2010 against 2009 andregain lost market share. We lost between 0.5% and 0.7% of themarket," said Dragos Damian in an interview with ZF."Overregulation has cost Terapia Ranbaxy a lot. On the other hand,in top ten Terapia Ranbaxy products we are market leaders. Maybe wehaven't focused enough on the second tier, products launched in thepast three to four years. These are two main causes, but there arealso others (...)," explained Damian. He says another goal for thisyear is to "optimise the Daiichi Sankyo hybrid model", a modelentailing the launch of products belonging to the parent company onthe domestic market, through Terapia Ranbaxy. "A third goal is thatthe base we created for Europe should develop in Romania. We'removing production of some drugs from India to Romania for Europeand the ex-Soviet space (...)" Damian said.
Pentru alte știri, analize, articole și informații din business în timp real urmărește Ziarul Financiar pe WhatsApp Channels
